COLL - コレギウム・ファ―マシュ―ティカル (Collegium Pharmaceutical Inc.) コレギウム・ファ―マシュ―ティカル

 COLLのチャート


 COLLの企業情報

symbol COLL
会社名 Collegium Pharmaceuticals Inc (コレギウム・ファ―マシュ―ティカル)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 医薬品   医療関連(Health Care)
概要 事業概要 コレギウム・ファーマシューティカル(Collegium Pharmaceutical Inc.)は特殊医薬品会社である。同社は、慢性疼痛及びその他疾患の治療用「DETERx」プラットフォーム技術を組み込んだ乱用防止製品の開発・製品化を行う。同社の製品はXtampza ERとONSOLISを含む。DETERxプラットフォームは、鎮痛、咀嚼、加熱および注射を含む一般的な乱用と改ざんの方法に対して保護しながら、徐放性ドラッグデリバリーを提供する。Xtampza ERは、一般的な乱用と偶発的な誤用を受けた後、徐放性薬物放出プロファイルを維持しながら、適切な疼痛管理を提供するように設計された。ONSOLISは、永続的な癌の痛みのために既にオピオイド療法を受けて耐性がある18歳以上のがん患者(BTPc)における突破痛の管理を目的とする経粘膜即時放出フェンタニル(TIRF)フィルムである。   コレギウム・ファ―マシュ―ティカルは米国の製薬会社。慢性疼痛および他の疾患の治療用に開発された特許取得済みプラットフォ―ム技術「DETERx」を組み込んだ、次世代の医薬品の開発、製品化を手掛ける。開発中の医薬品に「Xtampza ER」や「Xtampza」がある。   Collegium Pharmaceutical Inc. is a specialty pharmaceutical company committed to being the leader in responsible pain management. Collegium's headquarters are located in Stoughton, Massachusetts.
本社所在地 780 Dedham Street Suite 800 Canton MA 02021 USA
代表者氏名 Michael Thomas Heffernan マイケル・トーマス・ヘファナン
代表者役職名 Chairman of the Board President 取締役会長会長
電話番号 +1 781-713-3699
設立年月日 37347
市場名 NASDAQ National Market System
ipoyear 2015年
従業員数 250人
url www.collegiumpharma.com
nasdaq_url https://www.nasdaq.com/symbol/coll
adr_tso
EBITDA EBITDA(百万ドル) 11.26000
終値(lastsale) 16.98
時価総額(marketcap) 564104533.92
時価総額 時価総額(百万ドル) 571.41330
売上高 売上高(百万ドル) 159.55400
企業価値(EV) 企業価値(EV)(百万ドル) 449.16630
当期純利益 当期純利益(百万ドル) -62.37800
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Collegium Pharmaceutical Inc revenues increased from $5.7M to $136.8M. Net loss decreased 28% to $31.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Interest Income increase from $235K to $646K (income) Research and Development decrease of 1% to $3.8M (expense).

 COLLのテクニカル分析


 COLLのニュース

   Collegium Pharmaceutical, Inc. 2022 Q4 - Results - Earnings Call Presentation (NASDAQ:COLL)  2023/02/24 03:07:36 Seeking Alpha
The following slide deck was published by Collegium Pharmaceutical, Inc.
   Collegium Pharmaceutical, Inc. (COLL) Q4 2022 Earnings Call Transcript  2023/02/24 03:07:01 Seeking Alpha
Collegium Pharmaceutical, Inc. (NASDAQ:NASDAQ:COLL) Q4 2022 Earnings Conference Call February 23, 2023 4:30 PM ETCompany ParticipantsChristopher James - Vice President of Investor Relations…
   Collegium Pharmaceutical Non-GAAP EPS of $1.09 misses by $0.17, revenue of $129.62M beats by $4.41M  2023/02/23 21:45:04 Seeking Alpha
Collegium Pharmaceutical press release (COLL): Q4 Non-GAAP EPS of $1.09 misses by $0.17.Revenue of $129.62M (+373.8% Y/Y) beats by $4.41M.
   Collegium Pharmaceutical: Q4 Earnings Snapshot  2023/02/23 21:21:18 WTOP
STOUGHTON, Mass. (AP) — STOUGHTON, Mass. (AP) — Collegium Pharmaceutical Inc. (COLL) on Thursday reported a loss of $7.2 million…
   Earnings Outlook For Collegium Pharmaceutical  2023/02/22 16:00:59 Benzinga
Collegium Pharmaceutical (NASDAQ: COLL ) is set to give its latest quarterly earnings report on Thursday, 2023-02-23. Here''s what investors need to know before the announcement. Analysts estimate that Collegium Pharmaceutical will report an earnings per share (EPS) of $-0.14. Collegium Pharmaceutical bulls will hope to hear the company announce they''ve not only beaten that estimate, but also to provide positive guidance, or forecasted growth, for the … Full story available on Benzinga.com
   Collegium Pharmaceutical, Inc. 2022 Q1 - Results - Earnings Call Presentation (NASDAQ:COLL)  2022/05/16 17:37:57 Seeking Alpha
The following slide deck was published by Collegium Pharmaceutical, Inc.
   Collegium Pharmaceutical, Inc. (COLL) CEO Joe Ciaffoni on Q1 2022 Results - Earnings Call Transcript  2022/05/11 02:45:07 Seeking Alpha
Collegium Pharmaceutical, Inc. (NASDAQ:NASDAQ:COLL) Q1 2022 Earnings Conference Call May 10, 2022 04:30 PM ET Company Participants Alex Dasalla - Head of IR & Corporate Communications…
   Collegium Pharmaceutical GAAP EPS of -$0.39, revenue of $83.75M  2022/05/10 20:29:08 Seeking Alpha
Collegium Pharmaceutical press release (COLL): Q1 GAAP EPS of -$0.39.Revenue of $83.75M (-4.5% Y/Y).2022 Guidance: Total product revenues are expected in the range of $450.0 million…
   Collegium Pharmaceutical Q1 2022 Earnings Preview  2022/05/09 21:35:48 Seeking Alpha
Collegium Pharmaceutical (COLL) is scheduled to announce Q1 earnings results on Tuesday, May 10, after market close.The consensus EPS estimate is $0.90 and the consensus revenue estimate…
   Collegium to Host Conference Call to Discuss First Quarter 2022 Financial Results  2022/04/26 20:00:00 GlobeNewswire
STOUGHTON, Mass., April 26, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified specialty pharmaceutical company, today announced that the Company will host a conference call and live audio webcast on Tuesday, May 10, 2022 at 4:30 p.m. ET. The Company will discuss its first quarter 2022 financial results and provide a corporate update.
   Collegium Announces Four Posters Presented at PAINWeek 2021 National Conference  2021/09/13 12:00:00 Intrado Digital Media
STOUGHTON, Mass., Sept. 13, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that four poster presentations highlighting data regarding its product portfolio were presented at the Annual PAINWeek National Conference, which took place September 7-11, 2021 in Las Vegas, NV.
   Collegium to Participate in Upcoming Investor Conferences  2021/09/01 20:01:00 Intrado Digital Media
STOUGHTON, Mass., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a specialty pharmaceutical company committed to being the leader in responsible pain management, today announced that management will participate in the following investor conferences during the month of September:
   Collegium Pharmaceutical, Inc. (COLL) CEO Joseph Ciaffoni on Q2 2021 Results - Earnings Call Transcript  2021/08/07 19:27:06 Seeking Alpha
   Collegium Stock Is Getting Beaten As Q2 Earnings Miss Street Estimates; Revises FY21 Guidance  2021/08/06 16:21:40 Business Insider Markets
Collegium Pharmaceutical Inc (NASDAQ: COLL ) reported Q2 adjusted EPS of $0.27, below the consensus of $0.36.
   Collegium Pharmaceutical, Inc. 2021 Q2 - Results - Earnings Call Presentation  2021/08/06 14:37:19 Seeking Alpha

 関連キーワード  (医薬品 米国株 コレギウム・ファ―マシュ―ティカル COLL Collegium Pharmaceutical Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)